RxDoctor Payments Data

Julio Ramirez, MD

Internal Medicine · Bronx, NYNPI 1962494948

Payments from drug & device makers

$2,489in general payments, 2019–2025

Across 55 payments — averaging $45.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$857
  • Novo Nordisk$286
  • Xeris Pharmaceuticals, Inc.$273
  • Exact Sciences$195
  • Bayer$190
  • Phathom Pharmaceuticals, Inc.$149
  • plus $540 from 11 others

What the payments were for

  • Food & beverage$2,47699%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,489 in reported general payments places this provider in the 80th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$5,381
Medicare patients
20
Services billed
73

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin459$465,824
FarxigaDapagliflozin Propanediol219$213,133
OzempicSemaglutide214$208,868
TrulicityDulaglutide167$182,766
JanumetSitagliptin Phos/Metformin Hcl113$122,830
EliquisApixaban115$106,635
MounjaroTirzepatide98$106,331
SynjardyEmpagliflozin/Metformin Hcl102$92,283
JanuviaSitagliptin Phosphate84$78,640
LinzessLinaclotide110$75,077
Janumet XrSitagliptin Phos/Metformin Hcl57$50,242
Synjardy XrEmpagliflozin/Metformin Hcl50$43,946
Soliqua 100-33Insulin Glargine/Lixisenatide47$36,495
XareltoRivaroxaban41$35,670
Xigduo XrDapaglifloz Propaned/Metformin18$28,234

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy, Synjardy Xr, Tradjenta, Jentadueto$857$642,947656 claims
Lilly USA, LLCTrulicity, Mounjaro$46$289,097265 claims
AstraZenecaFarxiga, Lokelma, Brilinta$41$234,243251 claims
Novo NordiskOzempic, Rybelsus$286$233,933230 claims
PfizerEliquis$29$106,635115 claims
AbbVieLinzess$63$75,077110 claims
Johnson & JohnsonXarelto$35$35,67041 claims
GSKBreo Ellipta, Trelegy Ellipta, Shingrix$15$35,00295 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →